New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2014
07:40 EDTARIA, JAZZARIAD volatility is expected to move on acquisition rumors reports
ARIAD (ARIA) volatility is expected to move on rumors suggest that Jazz Pharmaceuticals (JAZZ) is willing to pay $20-plus per share to acquire ARIAD, Daily Mail says. Overall option implied volatility of 81 is below its 26-week average of 100 according to Track Data, suggesting decreasing price movement.
News For ARIA;JAZZ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 30, 2015
07:24 EDTJAZZStifel to hold a bus tour
BioTrek: 2015 West Coast Healthcare Therapeutics Bus Tour travels throughout San Francisco on March 30-April 1.
March 27, 2015
06:17 EDTJAZZJazz Pharmaceuticals assumed with a Buy at Citigroup
Price target lowered to $195 from $202.
March 26, 2015
07:30 EDTJAZZDeutsche Bank to hold a conference
Pharma One-on-One Day is being held in Denver, Colorado on March 26.
March 25, 2015
09:29 EDTARIAARIAD reports dismissal of class action suit in federal district court
ARIAD Pharmaceuticals announced that the United States District Court for the District of Massachusetts dismissed the shareholder class action lawsuit filed in late 2013 against the company and certain of its officers, directors and underwriters in connection with the events leading up to the temporary suspension of the marketing and commercial distribution of Iclusig on October 31, 2013, and subsequent re-launch in January 2014 based on revised U.S. prescribing information and a risk evaluation and mitigation strategy. The suit alleged that certain of the company defendants made a series of false and misleading statements regarding the safety, efficacy and commercial prospects of Iclusig. The Court granted the company’s motion to dismiss the lawsuit, concluding that the plaintiffs failed to establish that any such statements violated the company’s disclosure obligations as asserted in the complaint. “We are pleased that for the second time in as many weeks, the Court has granted our motion to dismiss what we believed from the outset was another meritless lawsuit,” said Harvey J. Berger, M.D., chairman and CEO. “Our corporate values of integrity and mutual respect are always at the forefront as we continue to focus on executing our plan for sustained revenue growth and operational excellence, leading to anticipated profitability in 2018.”
March 24, 2015
09:22 EDTARIAOn The Fly: Pre-market Movers
Subscribe for More Information
07:37 EDTARIAARIAD announces approval of Iclusig in Israel
ARIAD Pharmaceuticals and Medison Pharma announced that the Israeli Ministry of Health has granted regulatory approval for Iclusig, ponatinib, in Israel for adult patients with: Chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia who are resistant to dasatinib or nilotinib, who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate, or who have the T315I mutation Philadelphia chromosome-positive acute lymphoblastic leukaemia who are resistant to dasatinib, who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate, or who have the T315I mutation. ARIAD submitted its application for Iclusig to the Israeli Ministry of Health in June 2014. Commercial launch of Iclusig is expected to occur in Q2.
March 18, 2015
13:05 EDTJAZZJazz Pharmaceuticals management to meet with Piper Jaffray
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use